Study Summary
This is a phase I, open-label, dose-escalation clinical trial. The primary objectives are to assess the safety of PA3-17 injection in pediatric and adolescent participants with relapsed/refractory T-lymphoblastic leukemia/lymphoma, and determine the recommended phase II dose of PA3-17 injection for this patient population. Secondary objectives include evaluating the pharmacokinetics/pharmacodynamics, preliminarily assessing clinical efficacy, and evaluating the immunogenicity of the injection.
Interested in this trial?
Submit an InquiryInterventions
T cell injection targeting CD7 chimeric antigen receptorBIOLOGICAL
PA3-17 injection The subjects,who sign the informed consent forms and been screened by inclusion/exclusion criteria,will be assigned into 1.0\*10\^6,2.0\*10\^6 and 4.0\*10\^6 CAR-T/kg groups in order of sequence.And the subjects will be administered once.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| PersonGen Anke Cellular Therapeutice Co,Ltd. | Hefei | Anhui | China |